Pharmacyclics (PCYC +1.4%) moves up after Roth Capital ups its price target on the shares to $42...

|By:, SA News Editor

Pharmacyclics (PCYC +1.4%) moves up after Roth Capital ups its price target on the shares to $42 from $21. Roth thinks the market potential for the drug developer's lymphoma treatment ibrutinib is quite large, and it's impressed by the speed of the clinical program for the drug.